Search the GHTC website

Global health R&D delivers for Pennsylvania

US government investment in global health R&D has delivered

Amount
$352.8 million
to Pennsylvania research institutions
Jobs
4,300+ new jobs
for Pennsylvania
Pennsylvania's top USG-funded global health R&D institutions

Pennsylvania's top USG-funded global health R&D institutions

Magee-Womens Research Institute & Foundation
$107.3 million
University of Pennsylvania
$95.2 million
University of Pittsburgh
$69.2 million
Pennsylvania State University
$24.4 million
Drexel University
$20.4 million
Wistar Institute
$18.5 million
Particles Sciences
$3.4 million
Fox Chase Cancer Center/Institute for Cancer Research Philadelphia
$2.5 million
Children's Hospital of Philadelphia
$2.3 million
Baruch S. Blumberg Institute
$950 thousand
Duquesne University
$943 thousand
Philadelphia Research and Education Foundation
$651 thousand
Lehigh University
$451 thousand
Children's Hospital Pittsburgh - UPMC Health Systems
$408 thousand
Villanova University
$245 thousand
Temple University
$214 thousand
Pennsylvania Drug Discovery Institute
$204 thousand
Pennsylvania industry in global health R&D

Pennsylvania industry in global health R&D

Actuated Medical
Location(s): Bellafonte
AstraZeneca
Location(s): Philadelphia
Bayer
Location(s): Pittsburgh
Charles River Laboratories
Location(s): Horsham, King of Prusssia, Malvern
Fox Chase Chemical Diversity Center
Location(s): Doylestown
GSK
Location(s): Philadelphia, Upper Merion, Upper Providence
Immunotope
Location(s): Doylestown
Inovio Pharmaceuticals
Location(s): Plymouth Meeting
Integral Molecular
Location(s): Philadelphia
Janssen
Location(s): Horsham, Malvern, Spring House
L.E.A.F. Pharmaceuticals
Location(s): Woburn
Lenima Field Diagnostics
Location(s): Philadelphia
Lipella Pharmaceuticals
Location(s): Philadelphia
Medical Avatar
Location(s): Pittsburgh
Merck & Co
Location(s): Upper Gwynedd, West Point
Novartis
Location(s): Sinking Spring
Location(s): Philadelphia
Sanofi
Location(s): Malvern
VentoRx Pharmacueticals
Location(s): Malvern
Westat
Location(s): Philadelphia

Pennsylvania's top areas of global health R&D by USG funding

55.7%
HIV/AIDS
12.1%
Malaria
10.1%
Tuberculosis
3.5%
Diarrheal diseases
12.7%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
Trachoma
5.9%
Other
Bacterial pneumonia & meningitis
Ebola/viral hemorrhagic fevers
Salmonella infections
Global health R&D at work in Pennsylvania

Once HIV therapy is working, HIV can lie dormant in immune cells at low levels. It is critical to determine if this latent HIV reservoir, often containing damaged HIV, could create more virus and cause relapse if treatment is stopped. Now researchers at the University of Pittsburgh have created a test to detect this “hidden” HIV. The test is faster, easier on patients, less labor-intensive, less expensive, and more sensitive than the current gold-standard test.

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Scott Areman